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In Brief
CD5L operates as a critical switch of Th17
cells functional states, regulating their
ability to cause disease through changes
in lipid metabolism and function of the
master transcription factor Rorgt.
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Th17 cells play a critical role in host defense against
extracellular pathogens and tissue homeostasis but
can induce autoimmunity. The mechanisms impli-
cated in balancing ‘‘pathogenic’’ and ‘‘non-patho-
genic’’ Th17 cell states remain largely unknown.
We used single-cell RNA-seq to identify CD5L/AIM
as a regulator expressed in non-pathogenic, but
not in pathogenic Th17 cells. Although CD5L does
not affect Th17 differentiation, it is a functional switch
that regulates the pathogenicity of Th17 cells. Loss
of CD5L converts non-pathogenic Th17 cells into
pathogenic cells that induce autoimmunity. CD5L
mediates this effect by modulating the intracellular
lipidome, altering fatty acid composition and restrict-
ing cholesterol biosynthesis and, thus, ligand avail-
ability for Rorgt, the master transcription factor
of Th17 cells. Our study identifies CD5L as a crit-
ical regulator of the Th17 cell functional state and
highlights the importance of lipid metabolism in
balancing immune protection and disease induced
by T cells.
INTRODUCTION
IL-17-producing Th17 cells are present at tissue inflammation
sites and contribute to the pathogenesis of human autoimmune
diseases and relevant murine models (Kleinewietfeld and Hafler,
2013; Lee et al., 2014). However, not all Th17 cells induce tissue
inflammation and disease (i.e., are ‘‘pathogenic’’). Th17 cells thatline the normal gut mucosa regulate tissue homeostasis by
preventing invasion of gut microflora and promoting epithelial
barrier functions (Guglani and Khader, 2010). In addition, Th17
cells play a crucial role in host defense against pathogens such
as fungi (Candida albicans) and extracellular bacteria (Staphalo-
coccus aureus) (Gaffen et al., 2011; Romani, 2011). Therefore,
Th17 cells exhibit great diversity in their function. The extracel-
lular signals and intracellular mechanisms that control these
distinct functions of Th17 cells in vivo have not been identified.
Th17 cells with distinct effector functions can also be gener-
ated in vitro by different cytokine combinations. We (Bettelli
et al., 2006) and others (Mangan et al., 2006; Veldhoen et al.,
2006) found that two cytokines, IL-6 and TGF-b1, can differen-
tiate naive T cells into Th17 cells in vitro, although these cells
are poor inducers of experimental autoimmune encephalomy-
elitis (EAE), an autoimmune disease model for human multiple
sclerosis. Exposure to the pro-inflammatory cytokine IL-23 can
transform these cells into disease-inducing pathogenic Th17
cells (Awasthi et al., 2009; Cua et al., 2003; Ja¨ger et al., 2009;
Langrish et al., 2005; McGeachy et al., 2007; McGeachy et al.,
2009). Other cytokine combinations such as IL-1b+IL-6+IL-23
(Chung et al., 2009; Ghoreschi et al., 2010) or TGF-b3+IL-6+IL-
23 (Lee et al., 2012) can also induce Th17 cells that elicit EAE
with severe tissue inflammation. Comparing gene expression
profiles of Th17 cells generated with distinct in vitro differentia-
tion protocols led to the identification of a signature that distin-
guishes pathogenic from non-pathogenic Th17 cells (Lee et al.,
2012), consisting of 16 pro-inflammatory genes expressed in
pathogenic Th17 cells (e.g., T-bet, GMCSF and IL-23R) and 7
regulatory genes in non-pathogenic cells (e.g., IL-10). Exposure
of non-pathogenic Th17 cells to IL-23 converts them into a path-
ogenic phenotype, with diminished expression of the regulatory
signature and with acquisition of the pro-inflammatory signatureCell 163, 1413–1427, December 3, 2015 ª2015 Elsevier Inc. 1413
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genes, suggesting that IL-23 is a master cytokine that dictates
the functional phenotype of Th17 cells.
In humans, two subtypes of Th17 cells were described with
specificity for different pathogens. Th17 cells that co-produce
IL-17 with IFNgwere generated in response toCandida albicans,
whereas Th17 cells that co-produce IL-17 with IL-10 have spec-
ificity for Staphylococcus aureus infection (Zielinski et al., 2012).
Both IL-1 and IL-23 can differentially affect the development
of distinct Th17 subtypes in humans. Comparison of the hu-
man Th17 subsets with Th17 cells in mice suggests that the
C. albicans-specific Th17 cells may mirror the pathogenic Th17
cells we and others have described in mouse models of autoim-
munity with expression of proinflammatory signature genes,
whereas S. aureus-specific Th17 cells are more similar to the
non-pathogenic Th17 cells.
Identifying specific molecular switches that drive pathogenic
versus non-pathogenic Th17 cells will allow selective inhibi-
tion of pathogenic Th17 cells while sparing non-pathogenic,
potentially tissue-protective Th17 cells. To date, the intracellular
mechanisms by which IL-23 evokes the pathogenic phenotype
in differentiating Th17 cells are not well understood. Genomic
approaches provide a compelling unbiased method to find
such mechanisms (Wu et al., 2013; Yosef et al., 2013), but it is
likely that pathogenic and non-pathogenic cells co-exist in vivo
and co-differentiate in vitro, limiting our power to detect subtler
signals on a population level. Indeed, our previous study
comparing populations of in-vitro-derived pathogenic and non-
pathogenic cells (Lee et al., 2012) did not find strong candidate
regulators but, rather, effector molecules. The advent of single-
cell RNA-seq (Ramsko¨ld et al., 2012) opens the way to identify
such subtler yet physiologically important regulators.
Here, we used single-cell RNA-seq profiles of Th17 cells from
in vivo autoimmune lesions and from in vitro differentiation (Gau-
blomme et al., 2015, this issue of Cell) and identified a novel
regulator of Th17 pathogenicity, CD5-like (CD5L). CD5L is pre-
dominantly expressed in non-pathogenic Th17 cells and is
downregulated upon exposure to IL-23. Loss of CD5L converts
non-pathogenic Th17 cells into disease-inducing Th17 cells by
regulating the Th17-cell lipidome. CD5L decreases the level of
polyunsaturated fatty acyls (PUFA), affecting the expression of
key cholesterol biosynthesis enzymes and, in turn, affecting
the binding and activity of Rorgt, the master transcription factor
of Th17-cell differentiation. Thus, we discovered CD5L as a
critical regulator that distinguishes Th17 functional states andFigure 1. CD5L Is a Candidate Regulator of Th17 Cell Functional State
(A–C) Single-cell RNA-seq analysis. (A)Cd5l expression of single cells from in-vitro
EAE. (B and C) Correlation of Cd5l expression in non-pathogenic Th17 cells (T
signature of Lee et al., 2012); p = 2.63 3 105 (Wilcoxon rank-sum test, compar
founding signature genes of the single-cell-based proinflammatory (red) and regul
non-significant correlation).
(D–F) Validation of CD5L expression in vitro. Naive T cells (CD4+CD62L+CD44C
CD5L expression at 48 (D) and 72 hr (E) and by flow cytometry at 48 hr (F). (E) IL-
independent experiments.
(G–I) Validation of Cd5l expression in vivo. (G and H) IL-17A.GFP reporter mice we
the peak of disease. Cd5l and Il17a expression are measured by qPCR. Figure sh
experiments. (I) Cells were sorted from the gut of naive mice and the number o
Experimental Procedures).
See also Figure S1.identified T cell lipid metabolism as an integral component of
the pathways regulating Th17 cell pathogenicity.
RESULTS
Single-Cell RNA-Seq Identifies CD5L as a Candidate
Regulator of Pathogenicity
To identify regulators of Th17 cell function, we analyzed single-
cell RNA-seq profiles of Th17 cells isolated from the central
nervous system (CNS) during EAE in vivo or differentiated
in vitro under non-pathogenic (TGF-b1+IL-6) and pathogenic
(IL-1b+IL-6+IL-23) conditions (Gaublomme et al., 2015). We
used three lines of evidence to rank genes for their potential
association with pathogenicity: (1) transcript’s correlation with
the first principal component (PC) of single Th17 cells differ-
entiated in vitro (TGF-b1+IL-6), which showed the presence
of two anti-correlated modules: a ‘‘pro-inflammatory module’’
(positively correlated with Il17a expression) and a ‘‘regulatory
module’’ (positively correlated with Il10 expression); (2) co-varia-
tion of transcripts in vitro (TGF-b1+IL-6) with a cell pathogenicity
score, defined as the difference in the average expression of
genes from our previously defined pro-inflammatory and regula-
tory signatures (Lee et al., 2012); and (3) transcript’s correlation
with the first two PCs of single Th17 cells isolated from the
CNS and lymph node during EAE in vivo. These showed that
Th17 cells span a functional spectrum along the first PC (from
effector, memory to exhausted state) and the second PC (from
a naive-like to terminally differentiated state).
Cd5l is one of the high-ranking genes by single-cell analysis of
potential regulators, exhibiting two surprising features: although
Cd5l is expressed in Th17 cells derived under non-pathogenic
conditions (Figure 1A), in these non-pathogenic cells, Cd5l posi-
tively correlates with the first PC of in-vitro-derived cells and
co-varies with other genes in the pro-inflammatory module
(Figures S1A–S1C). In addition, Cd5l positively correlates with
the cell pathogenicity score (Figures 1B and 1C). Comparing
Cd5l expression at the single-cell level in Th17 cells (sorted
IL-17.GFP+) derived in vitro showed that 80% of Th17 cells
derived with IL-1b+IL-6+IL-23 lacked Cd5l expression, whereas
Th17 cells differentiated with TGF-b1+IL-6 predominantly
expressed Cd5l (Figure 1A). Neither Th17 cells differentiated un-
der an alternative pathogenic condition (TGF-b3+IL-6), nor did
encephalitogenic Th17 cells sorted from the CNS of mice un-
dergoing active EAE expressed Cd5l at the single-cell levels
-generated and in-vivo-sorted Th17 cells (IL-17.GFP+) frommice at the peak of
GF-b1+IL-6) with (B) the cell pathogenicity score (based on the pathogenic
ing signature scores of Cd5l expressing versus non-expressing cells). (C) The
atory (green) modules (solid bars, significant correlation [p < 0.05]; striked bars,
D25) were sorted and differentiated as indicated and analyzed by qPCR for
23 or control was added at 48 hr in fresh media. Figures are summary of three
re immunized to induce EAE. Cells were sorted from spleen (G) and CNS (H) at
own is representative data of three technical replicates from two independent
f RNA transcripts measured by nanostring nCounter platform (Supplemental
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(Figure 1A). However, Cd5l expressed in non-pathogenic Th17
cells (unsorted single-cell analysis, Figure S1A) correlates with
the first PC and co-varies with the pro-inflammatory module (Fig-
ure S1B) that is indicative of the pathogenic signature (Fig-
ure S1C), as previously defined (Lee et al., 2012). Furthermore,
Cd5l correlates with the defining signature of the pro-inflamma-
tory module and negatively correlates with that of the regulatory
module (Figure 1C). Finally, it is among the top eight genes in the
single-cell-based pro-inflammatory module whose expression
most strongly correlates with our previously defined pathogenic
gene signature (Figure 1B, p = 2.63 3 105).
CD5L is a member of the scavenger receptor cysteine-rich
superfamily (Sarrias et al., 2004). It is expressed in macro-
phages and can bind cytosolic fatty acid synthase in adipocytes
following endocytosis (Miyazaki et al., 1999). CD5L is also a
receptor for pathogen-associated molecular patterns (PAMPs)
and may regulate innate immune responses (Martinez et al.,
2014). However, its expression has not been reported in
T cells, and its role in T cell function has not been identified.
CD5L Expression Is Associated with Non-pathogenic
Th17 Cells In Vitro and In Vivo
We hypothesized that the preferential expression of CD5L in
non-pathogenic Th17 cells, but in association with the pro-
inflammatory module, may reflect a unique role for CD5L in regu-
lating the transition between a non-pathogenic and pathogenic
state. While co-expression with the pro-inflammatory module
(Figure 1C) and correlation with a pathogenicity signature (Fig-
ure 1B) per se could suggest a function as a positive regulator
of pathogenicity, the apparent absence of CD5L from Th17 cells
differentiated in vitro under the pathogenic conditions or isolated
from lesions in the CNS (Figure 1A) suggested a more nuanced
role. We hypothesized that CD5L is a negative regulator of path-
ogenicity, explaining its absence from truly pathogenic cells.
In fact, mRNAs encoding negative regulators of cell states are
often positively co-regulated with the modules they suppress
in eukaryotes from yeast (Pe’er et al., 2002; Segal et al., 2003)
to human (Amit et al., 2007).
We first validated and extended our initial finding that CD5L is
uniquely expressed in non-pathogenic Th17 cells by analyzing
naive CD4 T cells cultured under various differentiation condi-
tions using qPCR and flow cytometry (Figures 1D–1F). At the
mRNA level, we found little Cd5l expression in Th0, Th1, or Th2
helper T cells and high expression in Th17 cells differentiated
with TGF-b1+IL-6 but low expression in Th17 cells differentiated
with IL-1b+IL-6+IL-23 or in iTregs (Figure 1D). Protein measure-
ments confirmed the presence of CD5L in a large proportion of
non-pathogenic Th17 cells (Figure 1F).
Next, we explored whether CD5L expression is associated
with less-pathogenic Th17 cells in vivo. We analyzed Th17 cells
isolated from mice induced with EAE. Th17 cells (CD3+CD4+IL-
17.GFP+) sorted from the spleen expressed Cd5l, but IL-17
T cells did not (Figure 1G). In contrast, Cd5l was not expressed
in Th17 cells from the CNS despite significant expression of
Il17 (Figure 1H), consistent with the single-cell RNA-seq data
(Figure 1A). Next, we analyzed Th17 cells frommesenteric lymph
nodes (mLN) and lamina propria (LP) of naive mice, where Th17
cells contribute to tissue homeostasis and mucosal barrier func-1416 Cell 163, 1413–1427, December 3, 2015 ª2015 Elsevier Inc.tion. IL-17+, but not IL-17 T cells harvested from mLN and LP,
expressed high levels of Cd5l (Figure 1I and data not shown).
Thus, CD5L is a gene expressed in non-pathogenic, but not
pathogenic, Th17 cells in vivo.
We asked whether IL-23, known to make Th17 cells more
pathogenic, can regulate Cd5l expression. We hypothesized
that, if CD5L is a positive regulator of IL-23-dependent pathoge-
nicity, its expression will be increased by IL-23, whereas if it is a
negative regulator, its expression will be suppressed. As IL-23R
is induced after T cell activation, we differentiated naive T cells
with TGF-b1+IL-6 for 48 hr and expanded them in IL-23 in fresh
media. IL-23 suppressed Cd5l (Figure 1E), consistent with these
cells acquiring a pro-inflammatory module and becoming
pathogenic Th17 cells and with our hypothetical assignment of
CD5L as a negative regulator of pathogenicity. CD5L expression
can be promoted by STAT3, but not RORgt (Figures S1D and
S1E). As IL-23 can enhance STAT3 function, further studies are
required to elucidate the pathways involved in regulating CD5L
expression.
CD5L Represses Effector Functions without Affecting
Th17 Differentiation
Toanalyze the functional role ofCD5L in vivo,we immunizedmice
withMOG35-55/CFA to induceEAE.CD5L
/mice exhibitedmore
severe clinical EAE that persisted for at least 28 days, whereas
wild-type (WT)micebegan recovering 12dayspost immunization
(Figure 2A). Similar frequencies of FoxP3+ CD4+ Treg cells were
found in WT and CD5L/ mice, suggesting that the increased
severity of the disease was not due to changes in the number
of Tregs in CD5L/ mice (Figure S2A). In contrast, more CD4
T cells produced IL-17, and fewer cells produced IFNg in the
CNS of CD5L/ mice (Figures 2A and S2B). In response to
MOG reactivation in vitro, cells from the draining lymph nodes
ofCD5L/mice showed higher proliferative responses and pro-
duced more IL-17 (Figures S2C and S2D). These observations
are consistent with either a direct or indirect role for CD5L in
defining Th17 cell function.
We studied the impact of CD5L on Th17 cells differentiated
from naive WT and CD5L/ T cells by analyzing signature
gene expression. CD5L deficiency did not affect Th17 differenti-
ation as measured by IL-17 expression (Figures 2B and 2C), nor
did it affect other Th17 signature genes, including Il17f, Il21, Il23r,
Rorc, or Rora (Figure 2D). Of note, under the non-pathogenic
differentiation condition, CD5L/ Th17 cells made less IL-10
(Figures 2C and 2D). These observations suggest that changes
in differentiation alone cannot explain the increased susceptibil-
ity to EAE in CD5L/mice but that CD5L may indeed affect the
internal state of differentiated Th17 cells.
We determined whether CD5L regulates effector/memory
Th17 cells by differentiation of non-pathogenic Th17 cells from
naive cells. Upon restimulation, more CD5L/ Th17 cells pro-
duced IL-17 and expressed IL-23R without affecting viability
(Figure 2E and data not shown), suggesting that CD5L deficiency
leads to more stable expansion of Th17 cells. Consistently,
CD5L/ Th17 cells expressed more Il17 and Il23r, less Il10,
and similar levels of Rorc or Rora (Figure 2F). Thus, CD5L does
not regulate Th17 cell differentiation but affects Th17 cell
expansion and/or effector functions over time. Similarly, effector
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Figure 2. CD5L Represses Effector Functions
without Affecting Th17 Cell Differentiation
(A) EAE was induced by MOG/CFA (40 mg) immuni-
zation. Left panel is pooled results from three inde-
pendent experiments. (Right) Cytokine profile of CD4
T cells isolated from CNS at day 15 post immunization
with summary data in Figure S2B.
(B–D) Naive splenic T cells were sorted and differen-
tiated with TGF-b1+IL-6 for 48 hr. Th17 cell signature
genes were measured by flow cytometry (B), ELISA
(C), and qPCR (D).
(E and F) Effector Th17 cells were differentiated as in
(B) and resuspended in fresh media with no cytokines
for 72 hr followed by restimulation. Gene profile was
measured by flow cytometry (E) and qPCR (F).
(G and H) Effector memory T cells (CD4+CD62L
CD44+) (G) or Effector memory Th17 cells (CD4+
CD62LCD44+RorgtGFP+) (H) were sorted from
spleen of naive mice and activated with TCR stimu-
lation. All figures are summary of three independent
experiments unless otherwise specified.
See also Figure S2.
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memory cells (CD4+CD62LCD44+) isolated ex vivo from
CD5L/ mice have higher frequencies of IL-17+ and lower fre-
quencies of IL-10+ cells (Figures 2G and S2E), possibly reflecting
the greater stability of Th17 cells that persist in the repertoire of
CD5L/ mice. To address whether Th17 cells isolated in vivo
also produced more IL-17 per cell, we sorted RORgt+ (GFP+)
effector/memory T cells from WT and CD5L/ mice and found
more IL-17+ and fewer IL-10+ cells in CD5L/ cells, suggesting
that RORgt+ cells are better IL-17 producers in the absence of
CD5L (Figure 2H and S2F).
CD5L Is a Major Switch that Regulates Th17 Cells
Pathogenicity
To determine whether loss of CD5L can convert non-patho-
genic Th17 cells into disease-inducing Th17 cells, we crossed
CD5L/mice to 2D2 transgenic mice expressing a T cell recep-
tor specific forMOG35-55/IA
b (Bettelli et al., 2003). NaiveCD5L/
2D2 T cells were differentiated with the non-pathogenic (TGF-
b1+IL-6) Th17 condition and transferred into WT recipients.
A similar frequency of IL-17+ T cells was generated from WT
and CD5L/ 2D2 naive cells (Figure 3A), consistent with the
observation that CD5L does not affect Th17 differentiation.
We compared clinical and histological disease progression in
the recipients of WT and CD5L/ 2D2 cells. As expected, recip-
ients (6 out of 13) of WT 2D2 Th17 cells showed little sign of EAE.
Strikingly, all (12 out of 12) CD5L/ 2D2 recipients developed
severe EAE with optic neuritis, had significant weight loss, and
developed more ectopic lymphoid follicle-like structures in the
CNS (Figures 3B and 3C), a hallmark of disease induced by path-
ogenic IL-23-treated Th17 cells (Peters et al., 2011). Thus, T-cell-
intrinsic expression of CD5L plays a pivotal role in restraining
Th17 cell pathogenicity. We analyzed the phenotype of T cells
from the CNS of mice undergoing EAE. The 2D2 CD5L/ Th17
cells retained more IL-17+ and fewer IL-10+ cells (Figures 3D
and S3A). A considerable proportion of endogenous T cells pro-
duced IL-10 compared to transferred 2D2 T cells (Figure S3A),
suggesting that extracellular IL-10 is not sufficient to restrain
the pathogenicity ofCD5L/ Th17 cells. WT 2D2 T cells also ac-
quired IFNg expression in vivo, whereas CD5L/ 2D2 T cells
produced little IFNg, suggesting that CD5L may also regulate
Th17 cell stability. Consistently, naiveCD5L/ 2D2 T cells trans-
ferred into WT hosts immunized with MOG35-55/CFA without
inducing EAE made more IL-17 and little IL-10 in contrast to
WT 2D2 T cells (Figures 3E and S3B).
As IL-23 suppresses CD5L (Figure 1E) and CD5L restrains
Th17 cell pathogenicity, we reasoned that sustained CD5L
expression should antagonize IL-23-driven pathogenicity. ToFigure 3. CD5L Is a Switch that Regulates Th17 Cell Pathogenicity
(A–D) Passive EAE is induced as previously described (Ja¨ger et al., 2009). Naive
transferred into syngeneic WT hosts. (A) Cytokine profile of 2D2 T cells after diffe
EAE. (C) Representative histology of optic nerve (top two panels, H&E stain) and
indicated by loss of normal blue staining of myelin in lower panels. (D) Cytokine p
Cells were gated on Va3.2+CD4+.
(E) CD45.1 WT recipients received 100,000 naive WT or CD5L/ 2D2 T cells a
Cytokine profile of 2D2 T cells was examined on day 10 in draining LN.
(F) Expression profile of pathogenicity signature genes in WT and CD5L/ Th17
least three independent experiments.
See also Figure S3.test this hypothesis, we generated a retroviral vector for ectopic
expression of CD5L. Naive 2D2 T cells were differentiated with
IL-1b+IL-6+IL-23, transduced with CD5L, transferred intoWT re-
cipients, and followed for weight loss and the development of
clinical EAE (Experimental Procedures). 2D2 T cells transduced
with CD5L (CD5L-RV 2D2) had a small reduction in IL-17 and
higher IL-10 levels (Figure S3C). Ectopic expression of CD5L in
pathogenic Th17 cells reduced their pathogenicity, as CD5L-
RV 2D2 recipients had reduced weight loss and a significant
decrease in the incidence and peak severity of EAE (Figures
S3D and S3E). Furthermore, CD5L-RV 2D2 Th17 cells trans-
ferred in vivo lost IL-17 production and began producing IFNg
(Figure S3F). Therefore, sustained expression of Cd5l in patho-
genic Th17 cells converts them to a less pathogenic and less sta-
ble phenotype in that these cells lose the expression of IL-17 and
acquire an IFNg-producing phenotype in vivo. This observation,
combined with the observation that the loss of CD5L converts
non-pathogenic Th17 cells into pathogenic Th17 cells in vivo, un-
equivocally supports the role of CD5L as a negative regulator of
the functional pathogenic state of Th17 cells.
Consistent with our functional findings, CD5L regulates
expression of several pathogenicity signature genes. We differ-
entiated naive WT and CD5L/ T cells with TGF-b1+IL-6.
CD5L/ Th17 cells upregulated several effector molecules of
the pathogenic signature, including Il23r, Il3, Ccl4, Gzmb, Lrmp,
Lag3, and Sgk1 and downregulated several non-pathogenic
signature genes, including Il10, Il9, andMaf as compared to WT
Th17 cells (Figure 3F). Several other signature genes were not
affected by the loss of CD5L, suggesting a more nuanced
mechanism.
CD5L Shifts the Fatty Acid Composition in Th17 Cell
Lipidome and Restricts Cholesterol Synthesis, an
Endogenous Source of Rorgt Ligand
As CD5L regulates lipid metabolism by binding to fatty acid
synthase in the cytoplasm of adipocytes (Kurokawa et al.,
2010), we hypothesized that CD5L could regulate Th17 cell func-
tion by regulating fatty acid (FA) profiles in T cells. We asked
whether lipid metabolites are regulated by CD5L and whether
any such changes are associated with the increased pathoge-
nicity of CD5L/ Th17 cells. We profiled the lipidome of WT
andCD5L/ Th17 cells differentiated under the non-pathogenic
(TGF-b1+IL-6) and pathogenic (TGF-b1+IL-6+IL-23) conditions
using a non-targeted approach. We detected 178 lipid metabo-
lites from Th17 cells, 39 of which showed differences among
various Th17-polarizing conditions (Figures 4A and S4A; p <
0.05, fold change > 1.5; Table S1). Strikingly, non-pathogenicWT or CD5L/ 2D2 splenic T cells were differentiated with TGF-b1+IL-6 and
rentiation at day 4. (B) Weight and clinical score of recipient mice undergoing
spinal cord (bottom four panels, Luxol fast blue-H&E stains). Demyelination is
rofile of WT and CD5L/ 2D2 cells isolated from CNS at day 27 post transfer.
nd were immunized the following day with MOG/CFA without pertussis toxin.
cells differentiated with TGF-b1+IL-6 as in Figure 2E. Data are summary of at
Cell 163, 1413–1427, December 3, 2015 ª2015 Elsevier Inc. 1419
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Figure 4. CD5L Shifts the Fatty Acid Compo-
sition of Th17 Cell Lipidome and Modulates
Rorgt Ligand Availability
(A–C) Lipidome analysis of Th17 cells showing
altered SFA/MUFA and PUFA composition be-
tween WT and CD5L/ Th17 cells (Experimental
Procedures). (A) Heatmap of 39 metabolites (rows)
with significantly different levels among any Th17
cell conditions (columns) and with a fold change of
at least 1.5. Median intensity of each metabolite is
shown (color bar is normalized per row). (B) Lipids
from the two clusters in (A) are partitioned based on
the length and saturation of their fatty acyl (FA) side
chains. Those carryingmore than one FA are further
grouped by their FAs with the least saturation or
longest carbon chain (in that order). Complete FA
profile is shown in Figures S4B and S4C. (C) Ratio
of specific lipids in WT versus CD5L/ Th17 cells
carrying various PUFA side chains. Phospholipids
included in this analysis: phosphatidylcholine,
phosphatidylethanolamine, phosphatidylserine,
and their respective lyso-metabolites. Neutral lipids
included in this analysis: triacylglyceride, diac-
ylglyceride, and monoacylglyceride. *p < 0.05 in
Student’s t test.
(D) Expression of cyp51 and sc4molmRNA inWT or
CD5L/ Th17 cells (TGF-b1+IL-6, left) or WT Th17
cells (TGF-b1+IL-6 with control or IL-23, right). SFA
(palmitic acid, 25 uM) or PUFA (arachidonic acid, 25
uM) was added at 48 hr and cells analyzed at 96 hr.
Data are summary of three independent experi-
ments.
See also Figure S4 and Table S1.WT Th17 cells had a unique lipidome profile that was distinct
from those of CD5L/ Th17 cells and WT Th17 cells differenti-
ated with TGF-b1+IL-6+IL-23 (Figures 4A and S4A).
We analyzed the FA profile and lipid class in the Th17 cell lipi-
dome. As we did not detect free FA except myristic acid, we
analyzed the FA content (side chain) of the lipids in Figure 4A.
WT non-pathogenic Th17 cells (compared toCD5L/ Th17 cells
of the same conditions) have increased polyunsaturated fatty
acid (PUFA), accompanied by a decrease in lipids containing
saturated (SFA) and monounsaturated fatty acids (MUFA) (Fig-
ure 4B).We then extended our analysis to the 178 lipids detected.
Not all PUFA are different in WT versus CD5L/ Th17 cells:
linoleic acid (C18:2) and linolenic acid (C18:3) are equally distrib-
uted in the lipidome, whereas downstream PUFA—in particular,
arachidonic acid (C20:4)—are elevated in WT non-patho-
genic Th17 cells (Figure S4B). In contrast, MUFA is equivalently
distributed, and the corresponding SFA is decreased in WT non-
pathogenic Th17 cells (Figure S4C). The PUFA increase in WT
non-pathogenic Th17 is equivalently distributed among the phos-
pholipid and neutral lipid compartments (Figure 4C), whereas the
relative decrease of SFA is only significant in phospholipid (Fig-1420 Cell 163, 1413–1427, December 3, 2015 ª2015 Elsevier Inc.ure S4C). Finally, comparing the differ-
ence in specific lipid species (Figure S4D),
we found a higher level of cholesterol
ester (CE), lysophosphatidylcholine (LPC),
and phosphatidylcholine (PC), as well as
decreased triacylglyceride (TAG) in boththe CD5L/ and more pathogenic cells (Figure S4D). Taken
together, these findings suggest that CD5L predominantly regu-
lates FA composition in Th17 cells, resulting in elevation of PUFA
andchanges inspecific lipid species, includingcholesterolmetab-
olites.Similar changesarealsoobserved inWTTh17cellsdifferen-
tiated under the pathogenic condition.
Cholesterol metabolites, such as oxysterols, can function as
agonists of Rorgt (Jin et al., 2010; Soroosh et al., 2014), and
the cholesterol synthesis pathway has been linked to the pro-
duction of endogenous Rorgt ligand. While we did not detect
any oxysterols or intermediates of cholesterol synthesis, the
higher level of cholesterol esters (Figure S4D) prompted us to
further investigate the cholesterol pathway.
We confirmed the higher intensity of free cholesterol in
CD5L/ Th17 cells using microscopy (Figure S4E). Next, we
analyzed the expression of cyp51 and sc4mol, two enzymes
of the cholesterol synthesis pathway responsible for gener-
ating endogenous Rorgt ligands (Santori et al., 2015), and found
both increased in CD5L/ Th17 cells or in pathogenic WT Th17
cells (Figure 4D), suggesting that this may be a common mech-
anism by which Th17 cells regulate their function.
A B
C D
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Figure 5. CD5L and PUFA/SFA Profile Regu-
late Rorgt Function in a Ligand-Dependent
Manner
(A and B) Rorgt ChIP-PCR analyses in WT and
CD5L/ Th17 cells. WT, CD5L/, and Rorgt/
Th17 cells were differentiated with TGF-b1+IL-6 for
96 hr. Enrichment of Rorgt binding to genomic re-
gions of Il17 (A) and Il10 (B) is measured using
qPCR. For fatty acid experiments, 10 mM of either
SFA (palmitic acid) or PUFA (arachidonic acid or
docosahexaenoic acid showed similar results) was
added to WT Th17 cell culture at day 0. Three in-
dependent experiments were performed.
(C, D) Rorgt transcriptional activity was measured
by luciferase reporter of Il17 promoter in EL4 cells
transfected with CD5L-RV at 0, 25, 50, 100 ng (C) or
100 ng with 7, 27 dihydroxycholsterol (5, 0.5, or
0.05 uM) (D).
(E) Naive WT T cells were activated without polar-
izing cytokines (Th0) and were infected with retro-
virus expressing Rorgt in the presence of control-RV
or CD5L-RV with or without FF-MAS (5 uM) as
a source of Rorgt ligand. Each dot represents an
independent infection.
(F) WT or CD5L/ naive cells were differentiated
with TGF-b1+IL-6. At 48 hr, cells were replated in
fresh media with either control or FF-MAS (5 uM) as
a source of Rorgt ligand. Cells were harvested for
FACS analysis 72 hr later. Data are summary of three
independent experiments.
See also Figure S5.We asked if the change in FA profile in CD5L/ Th17 cells is
responsible for the regulation of cyp51 and sc4mol. Indeed,
while SFA had a modest effect, PUFA abolished the increased
expression of the enzymes in CD5L/ Th17 cells (Figure 4D).
Thus, CD5L can regulate fatty acid composition in Th17 cells
and alter the cholesterol synthesis pathway, a source of Rorgt
ligand.
CD5L and PUFA/SFA Profile Regulate Rorgt Function in
a Ligand-Dependent Manner
We analyzed whether CD5L and the PUFA/SFA profile can alter
Rorgt binding and function. Our previous chromatin immunopre-
cipitation (ChIP)-Seq analysis (Xiao et al., 2014) suggested that
Rorgt binds at several sites in the promoter and intronic regions
of Il23r and Il17 and near CNS-9 of Il10 (Figure S5A), where other
Il10-regulating transcription factors, such as cMaf, also bind
(Xiao et al., 2014). As CD5L restrains IL-17 and promotes IL-10
in Rorgt+ Th17 cells (Figure 2H) and CD5L/ Th17 cells have
more cholesterol metabolites and lower PUFA (Figures 4A, 4B,
S4D, S4E), we hypothesized that CD5L regulates the expression
of IL-23R, IL-17, IL-10, and, in turn, pathogenicity by affecting
the binding of Rorgt to these targets by changing the SFA/
PUFA profile and cholesterol biosynthesis.
We assessed whether CD5L regulates Rorgt binding and tran-
scription using ChIP-PCR and luciferase reporter assays. ChIP
of Rorgt showed higher binding in the Il17 and Il23r region and
reduced binding to the Il10 region in CD5L/ Th17 cells despite
similar Rorgt expression compared to WT (Figures 5A, 5B, andS5B). Further, CD5L overexpression was sufficient to suppress
Rorgt-dependent transcription of Il17 and Il23r luciferase re-
porters (Figures 5C and S5C) and to enhance the transcription
of the Il10 reporter (Figure S5D). This effect of CD5L is not
observed with PPARg, another regulator of Il10, further support-
ing the hypothesis that the effect of CD5L depends on Rorgt
(Figure S5E).
We then examined whether changing the lipidome of WT Th17
cells with exogenous SFA or PUFA can regulate Rorgt binding
to genomic regions (Figures 5A, 5B, and S5B). SFA enriched
binding of Rorgt at Il17 and Il23r loci, and PUFA decreased
such binding (Figures 5A and S5B). Instead, PUFA increased
Rorgt binding to the Il10 CNS-9 locus (Figure 5B), suggesting
that manipulation of the lipid content of Th17 cells can indeed
modulate Rorgt binding to DNA.
We reasoned that, if CD5L regulates Rorgt transcriptional
activity by limiting Rorgt ligand, adding exogenous agonists of
Rorgt would rescue CD5L-induced suppression. Indeed, 7b,
27-dihydroxycholesterol, previously shown as an endogenous
ligand of Rorgt (Soroosh et al., 2014), rescued the CD5L-driven
suppression of Il17 reporter transcription, suggesting that ligand
availability partly contributes to the regulation of Rorgt function
by CD5L (Figure 5D). Consistently, CD5L inhibited IL-17 expres-
sion in unpolarized Th0 cells with ectopic Rorgt expression, and
this inhibition could be partially rescued by the addition of a
Rorgt ligand (Figure 5E). Addition of Rorgt ligand also increased
IL-17 production from non-pathogenic Th17 cells (Figure 5F),
suggesting that ligand restriction may be one of the mechanismsCell 163, 1413–1427, December 3, 2015 ª2015 Elsevier Inc. 1421
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Figure 6. PUFA/SFA Regulate Th17 Cell Function and Contribute to CD5L-Dependent Regulation of Th17 Cells
(A and B) Naive T cells were sorted from WT or IL-23RGFP reporter mice (A) or WT or Rorc/ mice (B) and were differentiated with TGF-b1+IL-6 followed by
addition of IL-23 at 48 hr in fresh media with either PUFA (arachidonic acid, 10 uM) or SFA (palmitic acid, 20 uM). Cells were analyzed by flow cytometry (A) or
qPCR (B) at 96 hr. The concentration of free fatty acids was predetermined in titration experiments (data not shown).
(legend continued on next page)
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bywhich CD5L regulates Th17 cell pathogenicity.We then deter-
mined whether SFA/PUFA regulate Rorgt activity through Rorgt
ligand. While Rorgt strongly transactivates the Il23r enhancer in
the presence of an agonistic ligand, the addition of PUFA to
the agonist ligand inhibited Rorgt-mediated Il23r transactivation
and enhanced Il10 transactivation (Figures S5F and S5G). Simi-
larly, adding SFA alone had little impact on Rorgt-dependent
transcription, but it modified the transcriptional effect of oxy-
sterol (Figures S5F and S5G). Thus, PUFA/SFA can modulate
Rorgt transcriptional activity via a Rorgt-ligand dependent
mechanism, although the precise mechanism of exogenous
PUFA and SFA require further studies. Taken together, these ob-
servations suggest that CD5L shifts the FA composition in the
lipidome, changes Rorgt ligand availability and Rorgt genomic
binding, and regulates Il23r and Il10, members of the proinflam-
matory versus regulatory modules.
PUFA/SFA Regulate Th17 Cells and Contribute to CD5L
Function
As CD5L/ Th17 cells have an altered balance in lipid satura-
tion and PUFA/SFA modulate Rorgt binding and function, we
analyzed the relevance of FA moieties to Th17 cell function
and their contribution to CD5L-driven Th17 cell pathogenicity.
We first tested the effect of PUFA/SFA on the generation of
Th17 cells. WT Th17 cells were differentiated with TGF-b1+IL-6
and expanded using IL-23 in fresh media with either PUFA or
SFA. PUFA suppressed IL-17 and IL-23R expression, consistent
with reduced transactivation in WT, but not in Rorgt/ Th17
cells, suggesting that PUFA can limit pathogenic Th17 cell func-
tion in a Rorgt-dependent manner (Figures 6A and 6B). CD5L/
Th17 cells differentiated with TGF-b1+IL-6 were also sensitive to
PUFA treatment, resulting in reduced percentage of IL-17+ CD4+
T cells (Figure 6C). In contrast, addition of SFA only slightly
increased the expression of both IL-17 and IL-23R expression,
and this effect was not significant, possibly because pathogenic
Th17 cells had already very high levels of SFA.
We studied the contribution of lipid saturation to Th17 cell
pathogenicity. We speculated that, if the balance of lipid satura-
tion distinguishes non-pathogenic WT Th17 cells and patho-
genic CD5L/ Th17 cells, the addition of SFA to WT and
PUFA to CD5L/ Th17 cells can result in reciprocal changes
in the transcriptional signature relevant to Th17 cell pathoge-
nicity. We analyzed the expression of a 312-gene signature of
Th17 cell differentiation and function (Yosef et al., 2013) in
SFA- or control-treated WT Th17 cells and in PUFA- or control-
treated CD5L/ Th17 cells differentiated with TGF-b1+IL-6. Of
those genes that are differentially expressed (Table S2, > 1.5
fold), PUFA-treated CD5L/ Th17 cells resemble WT non-path-
ogenic Th17 cells, and SFA-treated WT non-pathogenic Th17
cells aremore similar toCD5L/ Th17 cells (Figure 6D and Table
S2). qPCR analysis confirmed that PUFA and SFA reciprocally(C) Naive WT and CD5L/ T cells were differentiated with TGF-b1+IL-6 and we
analyzed at 96 hr.
(D and E) Same as in (C). PUFA (5 uM) or SFA (25 uM) were added after 48 hr. Cells
differentially expressed between any of the four samples and with a fold change
(subtracted by mean and divided by SD). All data are summary of three indepen
See also Table S2.regulated effector molecule expression of the pathogenicity
signature (Lee et al., 2012), including Il10, Il23r, Ccl5, Csf2, and
Lag3 (Figure 6E). Notably, in some cases, PUFA and SFA have
the same effects; for example, Il22 expression is increased
following either FA treatment. Taken together, these observa-
tions suggest that the balance of lipid saturation contributes
to CD5L-dependent regulation of Th17 cells by regulating the
Th17-cell transcriptome.
DISCUSSION
Th17 cells are a helper cell lineage capable of diverse functions
ranging from maintaining gut homeostasis and mounting host
defense against pathogens to inducing autoimmune diseases.
How Th17 cells can mediate such diverse and opposing func-
tions remains a critical open question. Addressing this is espe-
cially important since anti-IL-17- and Th17-based therapies
have been highly efficacious in some autoimmune diseases but
had no impact on others (Baeten and Kuchroo, 2013; Genovese
et al., 2010; Hueber et al., 2012; Leonardi et al., 2012; Papp et al.,
2012; Patel et al., 2013), even when Th17 cells have been genet-
ically linked to the disease process (Cho, 2008; Lees et al., 2011).
Using single-cell genomics we have addressed this issue and
have identified novel functional regulators of pathogenicity in
Th17 cells.
Here, we highlight and investigate CD5L as one of the novel
regulators that affect the pathogenicity of Th17 cells. We show
that: (1) among CD4 T cells, CD5L is highly expressed only in
non-pathogenic Th17 cells but, in them, positively co-varies
with a pro-inflammatory module, a pattern consistent with being
a negative regulator of pathogenicity; (2) CD5L does not affect
Th17 differentiation but affects their long-term expansion and
function; (3) CD5L deficiency converts non-pathogenic Th17
cells into pathogenic Th17 cells; (4) CD5L regulates lipid meta-
bolism in Th17 cells and alters their fatty acid composition; and
(5) change in the lipidome in CD5L/ Th17 cells affects the
ligand availability and binding of Rorgt to its target genes.
In a seemingly paradoxical way, CD5L is expressed only in
non-pathogenic Th17 cells but in co-variance with the pro-
inflammatory module. This observation led us to hypothesize
that CD5L is a negative regulator of a non-pathogenic-to-patho-
genic transition, since negative regulators are often known to
co-vary in regulatory networks with the targets that they repress
in organisms from yeast (Segal et al., 2003) to mammals (Amit
et al., 2007; Amit et al., 2009). Our functional analysis bears
out this hypothesis, suggesting that CD5L might indeed be ex-
pressed to restrain the pro-inflammatory module in the non-
pathogenic Th17 cells. Similarly, other genes with this specific
pattern, i.e., exclusive expression in non-pathogenic cells but
in co-variance with the pro-inflammatory module, may also
be repressors that quench pro-inflammatory effector functionsre replated in fresh media with control or 5 uM of PUFA at 48 hr. Cells were
were analyzed by nanostring analysis (D) or qPCR (E) at 96 hr. (D) Genes that are
of at least 1.5 are plotted in the heatmap. Color scale is normalized per row
dent experiments.
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and make Th17 cells non-pathogenic. Thus, depending on the
environmental context or trigger, non-pathogenic Th17 cells
can be readily converted into pathogenic Th17 cells by inhibiting
a single gene like CD5L. This is supported by our data showing
that IL-23R signaling can suppress CD5L and that persistent
CD5L expression inhibits the pro-inflammatory function of
Th17 cells. In addition to suppressing the pro-inflammatory
module, CD5L also promotes the regulatory module, acting as
a switch to allow rapid responses to environmental triggers
such that Th17 cells can change their functional phenotype
without intermediary pathways.
Both pathogenic and non-pathogenic Th17 cells are present in
peripheral lymphoid organs, but pathogenic Th17 cells appear at
sites of tissue inflammation (CNS) and non-pathogenic Th17
cells appear in the gut or othermucosal surfaces. This ismirrored
in the expression of CD5L. IL-23, which is present in the CNS
during EAE, can suppress CD5L and convert non-pathogenic
Th17 cells into pathogenic Th17 cells. At steady state, it is un-
known what promotes CD5L expression and non-pathogenicity
in the gut. TGF-b could be a candidate, given its abundance in
the intestine and its role in both differentiation of IL-10-producing
CD4 T cells in vivo (Konkel and Chen, 2011; Maynard et al., 2007)
and Th17 cell differentiation (Bettelli et al., 2006; Veldhoen et al.,
2006). Specific commensal bacteria (Ivanov et al., 2009; Yang
et al., 2014) and metabolites from microbiota (Arpaia et al.,
2013) can also regulate T cell differentiation. Notably, CD5L is
reported as a secreted protein and can recognize PAMPs (Mar-
tinez et al., 2014). It is possible that CD5L expressed by non-
pathogenic Th17 cells in the gut can interact with the immune
cells interacting with gut microbiota and can maintain gut toler-
ance and a non-pathogenic Th17 phenotype. Other CD5L-
expressing cells in the intestine may also contribute to such a
function. Therefore, the two functional states of Th17 cells may
be highly plastic, in that either pathogenic or non-pathogenic
Th17 cells can be generated by sensing changes in the tissue
microenvironment. CD5L is critical for maintaining the non-
pathogenic functional state of Th17 cells, and IL-23 rapidly sup-
presses CD5L rendering the cells pathogenic. This hypothesis
also predicts that non-pathogenic Th17 cells can be easily con-
verted into pathogenic Th17 cells by production of IL-23 locally in
the gut during inflammatory bowel disease.
How does CD5L regulate Th17 cell pathogenicity? We provide
evidence that CD5L can regulate Th17 cell function by regulating
intracellular lipid metabolism and limiting Rorgt ligand. CD5L
inhibits the de novo synthesis of fatty acid through direct binding
to fatty acid synthase. We discovered that, in Th17 cells, CD5L is
more than a general inhibitor, as it regulates the fatty acid
composition of PUFA versus SFA and MUFA. We showed that
CD5L suppresses the cholesterol synthesis pathway by regu-
lating critical enzymes sc4mol and cyp51, and the addition of
PUFA could reverse this phenotype. Importantly, exogenous
Rorgt ligand can rescue the suppressive effect of CD5L on
IL-17 expression. PUFA metabolites can function as ligands of
several transcription factors, and the exact mode of function
for PUFA requires further investigation. We showed that PUFA
limits ligand-dependent function for Rorgt, such that, in the pres-
ence of CD5L or PUFA, Rorgt binding to the Il17a and Il23r loci is
decreased, along with reduced transactivation of both genes,1424 Cell 163, 1413–1427, December 3, 2015 ª2015 Elsevier Inc.whereas binding at and expression from the Il10 locus is
enhanced. Notably, Rorgt’s ability to regulate Il10 expression
was not reported previously. As CD5L does not impact overall
Th17 cell differentiation, this suggests a nuanced effect of
CD5L and lipid balance on Rorgt function, enhancing its binding
to and transactivation at some loci while reducing it in others. In
Th17 cells, Stat3 and c-Maf can promote Il10 (Stumhofer et al.,
2007; Xu et al., 2009). As Stat3, C-Maf, and Rorgt can all bind
to the same Il10 enhancer element, it is possible that, depending
on the quality and quantity of the available ligands, Rorgt may
interact with other transcription factors and regulate Il10 tran-
scription. This supports a hypothesis in which the spectrum of
Rorgt ligands depends, at least in part, on the CD5L-regulated
PUFA versus SFA lipid balance in the cell, and these resulting
ligands can impact the specificity of Rorgt, allowing it to assume
a spectrum of functional states.
Several metabolic pathways are associated with Th17 cell
differentiation. HIF1a regulates Th17 cells through direct trans-
activation of Rorgt (Dang et al., 2011; Shi et al., 2011), and
acetyl-coA carboxylase influences the Th17/Treg balance
through the glycolytic and lipogenic pathways (Berod et al.,
2014). Mice harboring mutations in genes that regulate Th17
cell differentiation and function acquire an obese phenotype,
associating Th17 cell development with obesity (Ahmed and
Gaffen, 2010; Jhun et al., 2012; Mathews et al., 2014; Winer
et al., 2009). A hallmark of obesity is the accumulation of satu-
rated fat and cholesterol, and mice fed with a diet rich in PUFA
were reported to have reduced severity of chronic colitis and
Th17 cell polarization (Monk et al., 2012, 2013). In this study,
we provided evidence that, at the cellular level, lipidome satura-
tion can promote Th17 cell function by regulating Rorgt function.
In conclusion, by using single-cell genomics and computa-
tional analysis, we identified CD5L as a novel repressor of Th17
cell pathogenicity, highlighting the power of single-cell genomics
to identify molecular switches that are otherwise obscured by
population-level genomic profiles. CD5L appears to be a molec-
ular switch that does not affect Th17differentiation per se but one
that impacts the function (pathogenic versus non-pathogenic
phenotype) of Th17 cells, potentially by regulating the quality
and/or quantity of available Rorgt ligands, allowing a single
master regulator to possibly assume multiple functional states.
Our results connect the lipidome to essential functions of immune
cells, opening new avenues for sensitive and specific therapeutic
intervention.
EXPERIMENTAL PROCEDURES
For additional procedures, please refer to the Supplemental Experimental
Procedures.
Single-Cell RNA-Seq Data Acquisition and Analysis
We profiled the transcriptome of 806 Th17 cells either harvested in vivo or
differentiated in vitro. For in vivo experiments, CD3+CD4+IL-17A.GFP+ cells
were isolated from draining LNs and CNS of mice at peak of EAE. For
in vitro experiments, cells were sorted at 48 hr post induction of differentiation
of naive CD4+ T cells under different conditions. We had at least two inde-
pendent biological replicates for each in vivo and in vitro condition (except
for TGF-b3+IL-6 for which we only had one replicate), as well as two technical
replicates for two in vivo conditions. For analysis, refer to the Supplemental
Experimental Procedures.
Lipidomics
Th17 cells were differentiated from naive WT and CD5L/ T cells. Culture me-
dia were snap frozen. Cells were harvested at 96 hr. 103 106 cells per sample
were snap frozen and extracted in either 80% methanol (for fatty acids and
oxylipids) or isopropanol (for polar and nonpolar lipids). Two liquid chromatog-
raphy tandem mass spectrometry (LC-MS) methods were used to measure
fatty acids and lipids in cell extracts. Further details are provided in the Supple-
mental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2015.10.068.
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